TY - JOUR AU - Shaukat, Nabila AU - Nisar, Shazia AU - Sajid, Usman AU - Jan, Osman Ali AU - Mahmood, Amjad AU - Zahid, Huma PY - 2021/02/24 Y2 - 2024/03/29 TI - COMPARATIVE STUDY OF EFFECTIVENESS OF VENLAFAXINE, DULOXETINE AND SERTRALINE IN MANAGEMENT OF DIABETIC SENSORY NEUROPATHY JF - Pakistan Armed Forces Medical Journal JA - PAFMJ VL - 71 IS - 1 SE - Original Articles DO - 10.51253/pafmj.v71i1.4780 UR - https://pafmj.org/PAFMJ/article/view/4780 SP - 228-33 AB - <p><strong>Objective:</strong> To compare efficacy of 3 commonly prescribed anti-depressants from classes’ selective serotonin<br>reuptake inhibitor and serotonin-nor epinephrine reuptake inhibitors i.e. Venlafaxine, Duloxetine and Sertraline<br>in the management of diabetic sensory neuropathy in subjects with type 2 diabetes mellitus.</p><p><strong>Study Design:</strong> Comparative, prospective study.</p><p><strong>Place and Duration of Study:</strong> Combined Military Hospital Jhelum, Mar 2018 to Jul 2018.</p><p><strong>Methodology:</strong> This study included 94 patients with metabolically stable type 2 Diabetes Mellitus with diabetic<br>sensory neuropathy. Patients were randomly assigned into 3 treatment group, treatment group 1 (n1=29) receiving Venlafaxine 37.5mg × BD, treatment group 2 (n2=33) receiving duloxetine 30mg × BD and treatment group 3 (n3=25) receiving Sertraline 50mg × OD, each group being treated for 6 weeks, with optional dose titration fortnightly. The efficacy measure was done by revised Neuropathy Disability Score (NDS), measured at baseline and at the end of treatment period i.e. 6 weeks. The primary outcome of this study was “functional outcome” assessed by Disability Neuropathy scale (DNS) and overall improvement and adverse events were measured as secondary outcome measures.</p><p><strong>Results:</strong> There was significant improvement in Neuropathy Disability scale (DNS) at the end of treatment period<br>in all treatment groups from their baseline score, with comparable efficacy among all drug groups i.e. p-value<br>between venlafaxine and duloxetine, venlafaxine and sertraline were non-significant i.e. p&gt;0.05 except between<br>Duloxetine and Sertraline group where there was significant difference in efficacy (p&lt;0.05). Good, moderate and<br>mild improvement in symptoms was noticed in all study groups.</p><p><strong>Conclusion:</strong> Non-tricyclic Anti-depressants i.e. Venlafaxine..........</p> ER -